Companies

Beximco stirs the pot on experimental Covid drug remdesivir

PT Jyothi Datta Mumbai | Updated on May 22, 2020 Published on May 22, 2020

Representative image   -  Getty Images/iStockphoto

Starts selling the drug in Bangladesh; Gilead distances itself from development

Bangladesh-based Beximco Pharma has caused a stir in the marketplace with its announcement of being the first in the world to sell its version of remdesivir, an investigational drug from Gilead Sciences that’s being used against Covid-19.

Reacting to the development, the US-based Gilead said that it had “not provided a licence to Beximco or any other company in Bangladesh to manufacture remdesivir.” It further added that it could not comment or verify the authenticity or effectiveness of this product as it is not manufactured by Gilead or one of its licensed partners.

Even as scientific voices caution against the rampant use of the drug that has only got emergency use authorisation from the United States Food and Drug Administration, the Dhaka-based Beximco seems to have got a head start of sorts on the drug.

According to reports, the company has started selling the drug in Bangladesh, and was giving it free to state-run hospitals and at $71 a vial to private clinics. With reports quoting the Beximco head as saying they were receiving queries on the drug for export to other countries, this could trigger a turf war of sorts.

Voluntary licences

Just last week, Gilead had signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to bolster global supplies of remdesivir. The companies were Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan, who were licensed to make remdesivir and sell in 127 countries, including Bangladesh. “The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access,” the US biopharmaceutical company said.

Gilead’s voluntary licence to select companies had, however, struck a sour note with health advocacy groups who wanted all medicines, vaccines, medical technology and diagnostic solutions developed in these pandemic times to be free of monopolies and patents so they would be equally accessible to all countries and people. In fact, this call was also made to global Health Ministers who interacted virtually at the recently-concluded World Health Assembly of the World Health Organization.

Published on May 22, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.